After a strong recovery, biotech stocks have hit a rough patch. The XBI index climbed to nearly $170 in August, more than double its level a year earlier, but has since traded sideways and eroded as disappointing clinical readouts, higher interest rates, and election jitters weigh on investors. Cantor Fitzgerald analysts described the index as having "traded sideways for the past few months," while Raymond James noted a "notable change in tone" as some investors now see a drop as more likely than a year-end rally.
Meanwhile, the acquisition market is telling a different story. BioPharma Dive data show 26 private biotech companies have been bought this year in deals worth at least $50 million, compared with 21 public biotech acquisitions. William Blair's Michael Allwin attributes the surge to a backlog of private companies that stayed out of the IPO market and now have clinical data to show buyers. The median private acquisition has jumped from $496 million in 2023 to $1 billion in 2026, and these deals have already outpaced the prior eight years combined.
Not all analysts see the private M&A boom as a lasting shift. RBC Capital Markets' Brian Abrahams notes that the third quarter is typically slow for dealmaking and expects activity to rebound, historically unaffected by interest rate changes. A pickup in public company buyouts, he argues, could reassure investors and improve sentiment. For now, the sector is caught between cautious public markets and a record pace of private consolidation.